All Outputs (5)

In Vitro Anticancer Properties of Novel Bis-Triazoles (2022)
Journal Article
Saleh, M. M., Abuarqoub, D. A., Hammad, A. M., Hossan, M. S., Ahmed, N., Aslam, N., Naser, A. Y., Moody, C. J., Laughton, C. A., & Bradshaw, T. D. (2023). In Vitro Anticancer Properties of Novel Bis-Triazoles. Current Issues in Molecular Biology, 45(1), 175-196. https://doi.org/10.3390/cimb45010014

Here, we describe the anticancer activity of our novel bis-triazoles MS47 and MS49, developed previously as G-quadruplex stabilizers, focusing specifically upon the human melanoma MDA-MB-435 cell line. At the National Cancer Institute (NCI), USA, bis... Read More about In Vitro Anticancer Properties of Novel Bis-Triazoles.

Design, and synthesis of selectively anticancer 4-cyanophenyl substituted thiazol-2-ylhydrazones (2022)
Journal Article
Mehmood, H., Musa, M., Woodward, S., Hossan, M. S., Bradshaw, T. D., Haroon, M., Nortcliffe, A., & Akhtar, T. (2022). Design, and synthesis of selectively anticancer 4-cyanophenyl substituted thiazol-2-ylhydrazones. RSC Advances, 12(52), 34126-34141. https://doi.org/10.1039/d2ra03226k

Cyclization of substituted thiosemicarbazones with α-bromo-4-cyanoacetophenone allows rapid single-step sustainable syntheses of 4-cyanophenyl-2-hydrazinylthiazoles libraries (30 examples, 66–79%). All show anticancer efficacy against HCT-116 and MCF... Read More about Design, and synthesis of selectively anticancer 4-cyanophenyl substituted thiazol-2-ylhydrazones.

Apoferritin-Encapsulated Jerantinine A for Transferrin Receptor Targeting and Enhanced Selectivity in Breast Cancer Therapy (2022)
Journal Article
Abuzaid, H., Abdelrazig, S., Ferreira, L., Collins, H. M., Kim, D.-H., Lim, K.-H., …Bradshaw, T. (2022). Apoferritin-Encapsulated Jerantinine A for Transferrin Receptor Targeting and Enhanced Selectivity in Breast Cancer Therapy. ACS Omega, 7(25), 21473-21482. https://doi.org/10.1021/acsomega.2c00997

he O-acetyl (or acetate) derivative of the Aspidosperma alkaloid Jerantinine A (JAa) elicits anti-tumor activity against cancer cell lines including mammary carcinoma cell lines irrespective of receptor status (0.14 < GI50 < 0.38 μM), targeting micro... Read More about Apoferritin-Encapsulated Jerantinine A for Transferrin Receptor Targeting and Enhanced Selectivity in Breast Cancer Therapy.

Apoferritin-Encapsulated Jerantinine A for Transferrin Receptor Targeting and Enhanced Selectivity in Breast Cancer Therapy (2022)
Journal Article
Abuzaid, H., Abdelrazig, S., Ferreira, L., Collins, H. M., Kim, D. H., Lim, K. H., Kam, T. S., Turyanska, L., & Bradshaw, T. D. (2022). Apoferritin-Encapsulated Jerantinine A for Transferrin Receptor Targeting and Enhanced Selectivity in Breast Cancer Therapy. ACS Omega, 7(25), 21473–21482. https://doi.org/10.1021/acsomega.2c00997

The O-acetyl (or acetate) derivative of the Aspidosperma alkaloid Jerantinine A (JAa) elicits anti-tumor activity against cancer cell lines including mammary carcinoma cell lines irrespective of receptor status (0.14 < GI 50 < 0.38 μM), targeting mic... Read More about Apoferritin-Encapsulated Jerantinine A for Transferrin Receptor Targeting and Enhanced Selectivity in Breast Cancer Therapy.

Pro-inflammatory effects of silver nanoparticles in the intestine (2022)
Journal Article
Sousa, A., Bradshaw, T. D., Ribeiro, D., Fernandes, E., & Freitas, M. (2022). Pro-inflammatory effects of silver nanoparticles in the intestine. Archives of Toxicology, 96(6), 1551-1571. https://doi.org/10.1007/s00204-022-03270-w

Nanotechnology is a promising technology of the twenty-first century, being a rapidly evolving field of research and industrial innovation widely applied in our everyday life. Silver nanoparticles (AgNP) are considered the most commercialized nanosys... Read More about Pro-inflammatory effects of silver nanoparticles in the intestine.